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creativecommons.org/somes (NDEs) were quantified to identify biomarkers for prediction and staging of mild cognitive
impairment (MCI) and AD.
Methods: Plasma exosomes were extracted, precipitated, and enriched for neuronal source by anti-
L1CAM antibody absorption. NDEs were characterized by size (Nanosight) and shape (TEM) and
extracted NDE protein biomarkers were quantified by ELISAs. Plasma NDE cargo was injected
into normal mice, and results were characterized by immunohistochemistry to determine pathogenic
potential.
Results: Plasma NDE levels of P-T181-tau, P-S396-tau, and Ab1–42 were significantly higher,
whereas those of neurogranin (NRGN) and the repressor element 1-silencing transcription factor
(REST) were significantly lower in AD and MCI converting to AD (ADC) patients compared to
cognitively normal controls (CNC) subjects and stable MCI patients. Mice injected with plasma
NDEs from ADC patients displayed increased P-tau (PHF-1 antibody)–positive cells in the CA1 re-
gion of the hippocampus compared to plasma NDEs from CNC and stable MCI patients.
Conclusions: Abnormal plasma NDE levels of P-tau, Ab1–42, NRGN, and RESTaccurately predict
conversion of MCI to AD dementia. Plasma NDEs from demented patients seeded tau aggregation
and induced AD-like neuropathology in normal mouse CNS.
 2016 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
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The number of individuals suffering from Alzheimer’s
disease (AD) is expected to triple by 2050 if no preventative
measures are developed [1]. AD is a neurodegenerative pro-
cess that results in cognitive impairment far worse than what
would be expected as a result of normal aging. Mild cogni-uthor. Tel.: 11-858-246-0140; Fax: 11-858-246-
issman@ucsd.edu
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blished by Elsevier Inc. on behalf of the Alzheimer’s Associ
licenses/by-nc-nd/4.0/).tive impairment (MCI) often is a transitional stage between
normal aging and dementia and is distinguishable clinically
from AD and normal aging [2]. The prevalence of dementia
in the United States is approximately 1% to 2%, whereas the
prevalence of MCI is approximately 5% to 15% [2].
Although MCI is not associated with significant functional
impairment, it carries an increased risk of developing de-
mentia. MCI patients will progress to AD at a rate as high
as 10% to 15% per year [3]. Initiating treatment at the stage
of MCI has been the focus of much research activity because
clinical trials of treatments for established AD have failed.ation. This is an open access article under the CC BY-NC-ND license (http://
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underlying etiologies, there is great interest in identifying
biomarkers that predict conversion fromMCI toADdementia.
Moreover, this is likely to delineate a population that is
more responsive to preventative treatments. The most consis-
tent AD biomarkers have been identified in cerebrospinal fluid
(CSF) [4–7]. CSF biomarkers in combination with recently
improved neuroimaging have increased the rate of early
diagnosis of preclinical AD patients, but CSF studies require
invasive sample collection [8–14]. Studies have shown
overlap in CSF biomarkers among MCI patients who later
manifest AD, those who develop non-AD forms of dementia,
and those who never exhibit signs of dementia [8–14]. The
presence of nonspecific binding of imaging radiotracers in
AD cases, especially those for phosphorylated tau (P-tau),
may limit their utility as accurate and predictive biomarker
tools for diagnosis of preclinical AD [15]. Prognostic
uncertainty combined with the morbidity and the high
expense of repeated CSF sampling and neuroimaging
methods emphasizes the importance of seeking blood-based
tests that have high diagnostic and prognostic ability for AD.
The pathologic hallmarks of AD include amyloid-beta
(Ab)—containing plaques and neurofibrillary deposits of
P-tau protein. A recent study determined that elevated levels
of the pathogenic proteins P-T181-tau, P-S396-tau, and
Ab1–42 contained within neuron-derived exosomes
(NDEs) isolated from plasma accurately predicted the devel-
opment of AD up to 10 years before clinical onset [16].
Several biomarkers measurable in NDEs may predict the
transition of MCI to AD dementia [16–19].
Exosomes represent a subtype of secreted membrane ves-
icles (40–100 nm in diameter) of endosomal origin that are
released from most types of cells including neurons
[20,21]. Exosomes function in removal of damaged or
excess proteins and cellular substituents, and also shuttle
cargo, including proteins and RNAs between cells [22,23].
Exosomes are reported to contain amyloid-b precursor
protein and its metabolites (C-terminal fragments, amyloid
intracellular domain, and Ab) [22,24]. Tau aggregates also
may be packaged inside exosomes, some of which enter
CSF or may even transit from the brain into blood.
Although the neuro-pathogenic potential of NDEs has yet
to be investigated, their role as biomarkers is being clarified.
Synapse loss and dysfunction is another pathologic hall-
mark of AD. Although synapse loss is an early event in AD
pathogenesis, it is evident in all stages of AD [25–27].
Clinical pathological studies have shown that synapse loss
correlates more closely with the degree of memory
impairment than deposition of Ab and P-tau in the brain
[28,29]. Neurogranin (NRGN) is a post-synaptic protein
that is expressed exclusively in the brain, particularly in den-
dritic spines, and facilitates synaptic transmission [30].
Recently, elevated NRGN levels have been detected as a po-
tential AD biomarker. CSF levels of NRGNwere elevated in
both AD [26,27] and stable MCI patients [31] compared to
those of cognitively normal controls (CNC).Repressor element 1-silencing transcription factor (REST)
has also been identified as a potential AD biomarker. REST
represses expression of neural genes in non-neuronal cells
and enhances neuronal survival [32,33]. Central nervous
system (CNS) levels of REST rise gradually in normal
aging but are significantly reduced in brains of stable MCI
patients and virtually absent in AD brains [34]. Changes in
REST expression in response to neurodegeneration have yet
to be measured in the CSF, but levels of REST in plasma
NDEs are significantly lower in AD than in matched cogni-
tively normal controls [18].
In this study, we harvested exosomes from human
plasma and enriched the content of those originating from
neurons, termed NDEs, by absorption with anti-L1CAM
antibody. Plasma NDE preparations were characterized by
size (Nanosight) and shape (transmission electron micro-
scopy, TEM), and levels of proteins of interest were quan-
tified by ELISA. We analyzed the predictive value of
levels of established and novel AD-related proteins ex-
tracted from plasma NDEs for the clinical progression of
MCI to dementia, in the setting of biosamples collected in
a randomized clinical trial. Additionally, we investigated
the role that NDEs play in AD pathogenesis. Human
NDEs isolated from the plasma of CNC subjects, stable
MCI, and ADC patients were injected into the brains of
wild-type, C57/Bl6 mice. We report evidence that P-tau
species contained within plasma NDEs can propagate tau
aggregation and have high pathogenic potential.2. Methods
2.1. Study design, subject characterization, and tissue and
blood collection
Sixty plasma samples were acquired through the Alz-
heimer’s Disease Cooperative Study Biomarker Core at Uni-
versity of California, San Diego [3]. Four clinical cohorts
were identified: cognitively normal controls (CNC,
n 5 10); patients with an established diagnosis of mild to
moderate AD (AD, n5 10), patients with stable mild cogni-
tive impairment (MCI; n 5 20; mean age, 68.7 6 7.76,
Supplementary Table 1), and patients who transitioned
within 36 months from MCI to AD (ADC, n 5 20; mean
age 75.35 6 6.82, Supplementary Table 1). CNC, MCI,
and AD groups were initially defined based on CSFAb con-
centrations and cognitive status as indicated by a mini-
mental state examination score (MMSE): CNC, CSF Ab1–
42 level .190 pg/mL, and normal cognition (MMSE 27-
30); MCI, memory complaint, cutoff score on the Logical
Memory test, MMSE .24, intact ADL [3]; AD, CSF
Ab1–42 ,190 pg/mL and MMSE ,20. Patients in the
ADC group were identified based on progression to a clinical
diagnosis of AD during the clinical trial, and the MMSE
scores 36 months after initial examination are reported
(mean MMSE at month 36, 17.67 6 0.70 ADC versus
28.82 6 0.33 MCI, Supplementary Table 2).
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neuronal derived exosomes (NDEs) from plasma
Aliquots of 250 mL of plasma were incubated with
thromboplastin-D (Fisher Scientific, Inc., Hanover Park,
IL) followed by addition of calcium-free and magnesium-
free Dulbecco’s balanced salt solution (DBS22) with
protease inhibitor cocktail (Roche Applied Sciences, Inc.,
Indianapolis, IN) and phosphatase inhibitor cocktail (Pierce
Halt, Thermo Scientific, Inc., Rockford, IL) [17,18]. After
centrifugation, supernatants were incubated with
ExoQuick exosome precipitation solution (EXOQ; System
Biosciences, Inc., Mountain view, CA), and resultant
suspensions centrifuged at 1500! g for 30 minutes at
4C. Each pellet was re-suspended in 300 mL of distilled wa-
ter with inhibitor cocktails followed by immunochemical
enrichment of exosomes from neural sources [19].
Total exosome suspensions were incubated with 2 mg of
mouse anti-human CD171 (L1CAM, neural adhesion pro-
tein) biotinylated antibody (clone 5G3, eBioscience, San
Diego, CA) in 50 mL of 3%BSA for 60 min at 20C followed
by addition of 10 mL of Streptavidin-Plus UltraLink resin
(Pierce-Thermo Scientific, Inc.) in 40 mL of 3% BSA and
further incubation for 60 minutes [19]. After centrifugation
at 400 ! g for 5 minutes at 4C, pellets were resuspended
in 100 mL of 0.05-M glycine-HCl (pH 3.0), incubated at
4C for 10 minutes, and re-centrifuged at 4000 ! g for
10 minutes at 4C. Each supernatant was transferred to a
new Eppendorf tube containing 10 mL of 1-M Tris-HCl
(pH 8.0) and 40 mL of 3% BSA, mixed and received
350 mL of M-PER mammalian protein extraction reagent
(Thermo Scientific, Inc.) containing protease and phospha-
tase inhibitors, mixed and stored at 280C.
L1CAM-positive NDE cargo proteins were quantified by
human-specific ELISAs for P-T181-tau (Fujirebio US, Inc.,
Alpharetta, GA), Ab1–42, and P-S396-tau (Life Technolo-
gies/Invitrogen, Camarillo, CA), REST (Cusabio, American
Research Products, Inc., Waltham, MA), Neurogranin
(Cloud-Clone Corp., American Research Products, Inc.),
and tetraspanning exosome marker CD81 (Cusabio- Amer-
ican Research Products, Inc.) with verification of the
CD81 antigen standard curve using purified human recombi-
nant CD81 antigen (Origene Technologies, Inc., Rockville,
MD), according to suppliers’ directions. The mean value
for all determinations of CD81 in each assay group was set
at 1.00, and the relative values for each sample were used
to normalize their recovery. Evidence for enrichment of exo-
somes from neural sources in plasma has been demonstrated
previously [17,19].2.3. Characterization of L1CAM-positive plasma NDEs
based on shape and size
L1CAM-positive plasma NDEs were characterized based
on size and shape using TEM as previously described [35].
NTA was used to characterize L1CAM-positive plasmaNDEs based on size distribution. NDEs from CNC (n 5 4)
and ADC (n 5 4) patients were pooled in 100 mL of
Phosphate buffer saline (PBS), diluted 1:2000, and visual-
ized with a NanoSight LM10 instrument as described [36].
2.4. Injection of L1CAM-positive NDEs from plasma into
normal mouse CNS and characterization by IHC
For all in vivo experiments, 2 mL of plasma NDEs from
either control, stable MCI or ADC patients were injected
into the right hippocampus of wild-type, C57/BL6 mice
(n 5 6/group, 8–10 month old) at the level of (22.0,
11.5, 21.3) (from Bregma, lateral, into) and analyzed 1
month after injection using immunohistochemistry (IHC).
Brain slices containing hippocampus were probed using
the anti-P-tau (PHF-1) antibody as described [37].
Frozen sections of 30 mM thickness were cut on a sliding
microtome and stored at 220C in cryoprotectant solution
(20% glycerol and 30% ethylene glycol in 0.1-m phosphate
buffer). PHF-1 was used to detect P-tau (1:500 dilution) in
free-floating sections containing hippocampus using
Mouse-on-Mouse Immunodetection Kit reagents (Vector
Laboratories, Burlingame, CA) to avoid detection of endog-
enous mouse Ig. Endogenous peroxidase was quenched with
0.3% hydrogen peroxide to reduce free aldehydes. Reaction
product was developed using a nickel-enhanced glucose ox-
idase method [38].
2.5. Statistical analyses
The statistical significance of differences between means
for cross-sectional patient groups and between each patient
group and their respective control group was determined
with by one-way ANOVA with Newman–Keuls Multiple
Comparison post hoc test (GraphPad Prism 6, La Jolla,
CA). Discriminant classifier analyses were conducted by
the Wilks’ Lambda method to assess the performance of
each NDE protein and the combined set in patient classifica-
tion as described. Receiver operating characteristic (ROC)
analyses were conducted under the non-parametric distribu-
tion assumption for standard error of area to determine the
performance of classifier models (SPSS v21.0, IBM).3. Results
3.1. Characterization of plasma L1CAM-positive plasma
NDEs of stable MCI and ADC patients
Plasma NDEs were analyzed for morphology and size
distribution using TEM and a Nanosight system, respec-
tively (Fig. 1). TEM revealed a homogenous population of
morphologically distinctive particles of approximately
100-nm diameter for all patient populations (Fig. 1A;
Plasma NDEs from stable MCI patients only; n 5 4/group;
scale bars, 350 nm and 100 nm). Nanoparticle tracking anal-
ysis detected a high concentration of plasma NDEs from
both stable MCI (9.52 6 1.93 ! 1011 particle/mL) and
Fig. 1. Plasma NDEs derived from stable MCI and ADC patients are similar in size and shape to previously reported exosome preparations. (A) Representative
TEM image of plasma NDEs derived from a stable MCI patient (scale bars 350 nm; 100 nm). NTA detects high concentrations of plasma NDEs (B) with similar
size distributions (C) that are not significantly different between the two patient populations. (C) Representative NTA plot of averaged size/concentration for
plasma NDEs derived from a MCI and ADC patient (n 5 4/group). Abbreviations: NDE, neuronal derived exosome; MCI, mild cognitive impairment; ADC,
MCI converting to AD; TEM, transmission electron microscopy; NTA, nanoparticle tracking analysis.
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diameter distributions (Fig. 1B, 89.75 6 2.15 nm vs.
94.5 6 4.48 nm). Human plasma thus is a reliable source
of authentic NDEs that are similar in appearance and size
to those previously reported [20,21,39].3.2. Plasma NDE cargo contains P-T181-tau, P-S396-tau,
Ab1–42, NRGN, and REST
Plasma NDEs were isolated from the four clinical co-
horts and their protein cargo were extracted and analyzed
by enzyme-linked immunosorbent assays (ELISAs).
Plasma NDEs from all patient groups and controls had
indistinguishable levels of the exosome membrane marker
protein CD81 (Fig. 2A). For ADC patients, CD81-
normalized NDE concentrations of biomarkers were signif-
icantly higher than those of CNC subjects: Ab1–42
(Fig. 2B, 22.07 6 4.336 pg/mL vs. 2.979 6 0.4485 pg/
mL, P , .0001), P-T181-tau (Fig. 2C, 256.5 6 31.15 pg/
mL vs. 69.74 6 8.319 pg/mL, P , .0001), and P-S396-
tau (Fig. 2D, 32.32 6 4.604 pg/mL vs. 11.15 6 1.769
pg/mL, P , .0001). Similarly, for AD patients, CD81-
normalized NDE concentrations of Ab1-42 (17.38 6
3.790 pg/ml, P , 0.05), P-T181-tau (191.3 6 15.06
pg/ml, P , 0.05), and P - S396-tau (31.95 6 3.100
pg/ml, P , 0.0001) and and were all significantly higherthan those of CNC subjects. Interestingly, of the three
core AD biomarker analytes quantified, only CD81-
normalized NDE concentrations of P-T181-tau were
significantly increased in stable MCI patients compared
to those of CNC subjects (Fig. 2C, 155.1 6 17.29 pg/
mL, P , .05).
For inter-patient group analyses, CD81-normalized
NDE concentrations of P-T181-tau (P , .001), P-S396-
tau (P , .001), and Ab1–42 (P , .01) all were signifi-
cantly higher in ADC patients than in stable MCI patients.
CD81-normalized NDE concentrations of P-S396-tau
(P , .001) and Ab1–42 (P , .01), but not P-T181-tau,
were significantly higher in AD patients than in stable
MCI patients.
CD81-normalized NDE concentrations of neurogranin
(NRGN) were significantly lower in stable MCI patients
(Fig. 2E, 253.7 6 27.58 pg/mL vs. 356.5 6 26.07 pg/mL,
P , .01), ADC patients (Fig. 2E, 55.74 6 12.70 pg/mL
P , .0001) and AD patients (Fig. 2E, 50.29 6 11.16
pg/mL, P , .001) than in CNC subjects. Furthermore,
CD81-normalized NDE concentrations of NRGN were
significantly lower in ADC patients (P , .0001) and AD
(P , .0001) than in stable MCI patients. Similarly, CD81-
normalized NDE concentrations of RESTwere significantly
lower in ADC patients (Fig. 2F, 32.97 6 4.161 pg/mL) and
in AD patients (Fig. 2F, 48.176 5.661 pg/mL) than in stable
Fig. 2. Human plasma NDE levels of P-T181-tau, P-S396-tau, Ab1–42, NRGN, and REST delineate stages of AD. (A) Plasma NDE levels of CD81 were not
statistically different among the four clinical cohorts as measured by ELISA. Significantly different levels of (B) Ab1–42, (C) P-T181-tau, (D) P-S396-tau, (E)
NRGN, and (F) RESTwere detected by ELISAs in the plasmas of CNC (n5 10), stable MCI (n5 20), ADC (n5 20), and AD (n5 10) patients. Plasma NDE
levels of P-T181-tau, P-S396-tau, and Ab1–42 were significantly higher, whereas those of NRGN and RESTwere significantly lower for ADC and AD patients
than CNC subjects and stable MCI patients. The horizontal line in each cluster depicts the mean for that set. *5 P, .05, **5 P, .01, ***5 P, .0001 versus
CNC; ## 5 P , .01, ###5 P , .0001 versus MCI. Abbreviations: NDE, neuronal derived exosome; CNC, cognitively normal controls; MCI, mild cognitive
impairment; ADC, MCI converting to AD.
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(829.9 6 148.4 pg/mL; P , .0001 for all differences). We
found no significant difference between CD81-normalized
NDE concentrations of REST in stable MCI patients as con-
trasted with CNC subjects.3.3. ROC analyses for patient characterization
ROC analysis was conducted in order to determine
if the diagnostic sensitivity of the five biomarkers individu-
ally or collectively increased their predictive ability indistinguishing two patient populations. (Fig. 3, see
Supplementary Tables 3–6). When all the plasma NDE
cargo proteins were considered individually, the sensitivity
for distinguishing CNC subjects from AD patients was
100% for P-T181-tau, NRGN, and REST (confidence
interval [CI]: 100%–100%) and 98% for P-S396-tau and
Ab1–42 (CI: 93%–100%; Fig. 3A). The sensitivity for
distinguishing CNC subjects from stable MCI patients
was 87.56 0.06351% for P-T181-tau (CI: 75%–99%);
78.36 0.08445% for P-S396-tau (CI: 62%–95%);
76.56 0.08617% for Ab1–42 (CI: 60%–93%),
Fig. 3. ROC curve analyses assess diagnostic accuracy for plasma NDEs levels of P-T181-tau, P-S396-tau, Ab1–42, NRGN, and REST. ROC curves based on
the plasma NDE levels of P-T181-tau, P-S396-tau, Ab1–42, NRGN, and REST for (A) CNC subjects versus AD patients, (B) CNC subjects versus stable MCI
patients, (C) stable MCI versus ADC patients, and (D) stable MCI versus AD patients. Abbreviations: ROC, receiver operating curve; NDE, neuronal derived
exosome; CNC, cognitively normal control; MCI, mild cognitive impairment; ADC, MCI converting to AD.
C.N. Winston et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 63-726877.86 0.08546% for NGRN (61%–95%); and
71.5 6 0.09499 for REST (CI: 53%–90%; Fig. 3B). The
sensitivity for distinguishing stable MCI patients from
ADC patients was 72.86 0.07906% for P-T181-tau (CI:
57%–88%); 97.56 0.01923% for P-S396-tau (CI: 97%–
100%); 97.86 0.02140% for Ab1–42 (CI:93.6%-100%);
97.2 6 0.02056% for NRGN (CI: 93.2 %–100%); and
100% for REST (CI: 100%–100%) (Fig. 3C). The sensitivity
for distinguishing stable MCI patients from AD patients was
100% for P-S396-tau, NRGN, and REST (CI: 100%–100%);
69.36 0.9475% for P-T181-tau (CI: 51%–88%); and
986 0.02229% for P-S396-tau (CI: 94%–100%) (Fig. 3D).
When plasma NDE levels of all the proteins were consid-
ered together, the sensitivity of distinguishing CNC subjects
from AD patients was 99.2%; the sensitivity of distinguish-
ing CNC subjects from stable MCI patients was 78.3%; the
sensitivity for distinguishing stable MCI patients from ADC
patients was 93.1%; and the sensitivity for distinguishing
stable MCI patients from AD patients was 93.2%.3.4. Human plasma NDEs with P-tau seed tau aggregation
in normal mice
To determine the neuropathogenic potential of NDEs
derived from human MCI and ADC plasma as compared
to controls alone, these preparations were injected into
the right hemisphere of 8–10 month old, C57/Bl6, femalemice. One month after injection, all mice were sacrificed,
and brain tissues were analyzed by IHC. We found that
mice injected with plasma NDEs from stable MCI and
ADC patients displayed PHF-1 immunoreactivity in the
CA1 region of the hippocampus, whereas no PHF-1
immunoreactivity was observed in the hippocampus of
mice injected with plasma NDEs from CNC subjects
(Fig. 4, n 5 6/group). PHF-1 immunoreactivity was rarely
observed in mice injected with plasma NDEs from stable
MCI patients, whereas a significant number of PHF-1 pos-
itive, pyramidal CA1 neurons were observed in mice that
were injected with plasma NDEs from ADC patients.
Moreover, diffuse staining of PHF-1 also extended into
the dendritic processes of PHF-1 positive neurons
observed in mice injected with plasma NDEs from ADC
patients.
Together, these data suggest that human plasma NDEs
carry pathogenic tau cargo capable of seeding the propaga-
tion of P-tau pathology in normal mice.4. Discussion
The current procedures of AD diagnostics are invasive
(CSF sampling), expensive (neuroimaging), and time
consuming (neuropsychological testing) [40]. The conse-
quent need for less invasive and more cost-effective tools
to identify AD at an early and perhaps more treatable stage
Fig. 4. Plasma NDEs from stable MCI and AD patients seed tau aggregation in the brains of normal mice. Representative photomicrographs of hippocampal
sections obtained from wild-type, C57/Bl6 mice that were injected with plasma NDEs from control, stable MCI, and ADC patients. At 1-month post-injection,
mice injected with plasma NDEs from stable MCI patients display modest enhancement of PHF-1 immunoreactivity in the CA1 region of the hippocampus,
whereasmice injectedwith plasmaNDEs fromADC patients display a significant increase in PHF-1 immunoreactivity in the CA1. Extensive cellular staining as
well as staining within the dendritic processes can be observed in these mice. Mice-injected NDEs from control plasma displayed no PHF-1 immunoreactivity
(n 5 6/group; scale bars 250 mm; 25 mm). Abbreviations: NDE, neuronal derived exosome; MCI, mild cognitive impairment; ADC, MCI converting to AD.
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study found that a combination of P-T181-tau, P-S396-tau,
and Ab1–42 contained within NDEs from blood predicted
the development of AD up to 10 years before clinical onset
[16]. Step-wise discriminant modeling of auto-lysosomal
protein levels [19], transcription factors [18], and phosphor-
ylated forms of the insulin receptor substrate [17] in plasma
NDEs have also correctly distinguished 100% of patients
with AD from normal controls. Our goal for characterizing
plasma NDEs was to create a profile that included primary
(P-tau and Ab1–42) and amplifying (NRGN and REST)
blood-based biomarkers that measure proteins related to
pathologic events of brain changes described in AD. Addi-
tionally, we wanted to determine the pathogenic potentialof AD-related proteins contained within plasma NDEs. In
the present study, we confirmed that plasma NDE protein
profiles can distinguish among different stages of AD and
predict which patients with clinically defined MCI are
most likely to progress to AD. Moreover, we demonstrated
for the first time that the plasma NDEs from ADC (and
MCI) patients may propagate tau pathology in the brains
of normal mice similar to that seen in human AD brains.
The diagnostic accuracy of the five different biomarkers
was assessed by ROC analysis. ROC analysis showed that
individually, all five biomarkers were highly predicative
(sensitivity, 98 to 100%) in distinguishing CNC subjects
from AD patients and from MCI patients who progressed
to AD. In contrast, the sensitivity to distinguish CNC
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more variable among the five biomarkers that were tested.
When plasma NDE levels of all the markers were consid-
ered together, the sensitivity of distinguishing CNC subjects
from stable MCI patients was 78.3%. When plasma NDE
levels of P-T181-tau, P-S396-tau, and Ab1–42 were consid-
ered together, the sensitivity of distinguishing CNC subjects
from stable MCI patients slightly increased to 80.8%.
AlthoughNRGN andRESTwere highly predictive for distin-
guishing AD patients from CNC subjects and MCI patients,
individually, their sensitivities were significantly less for dis-
tinguishing CNC subjects from MCI patients (77.8% and
71.6%, respectively). These data suggest that decreases in
plasma NDE levels of NRGN and REST may occur later
in AD progression. The most sensitive plasma NDE analyte
distinguishing CNC subjects from stable MCI patients was
P-T181-tau (sensitivity, 87.5 6 0.06351%), although
P-T181-tau was the least sensitive analyte for distinguishing
stable MCI patients from AD patients (sensitivity,
69.36 0.09475%).
In current clinical practice, the combination of P-tau and
Ab1–42 in CSF has provided the greatest predictive accu-
racy for the conversion of MCI to dementia [4–7]. One
study reported that a low Ab1–42/P-tau ratio in CSF was
the best predictor of cognitive decline and conversion to
AD in MCI patients [5]. In contrast, we find that a high
expression of P-tau and Ab1–42 in plasma NDEs, that reflect
CNS tissue levels of these biomarkers, was the best predictor
of the conversion from MCI to AD. It is possible that NDEs
reflect neuronal attempts to eliminate pathogenic proteins
during neurodegeneration.
Studies show that higher baseline CSF levels of NRGN in
MCI patients who progressed to AD correlated with a more
rapid loss of cognition [27] and were highly predictive of the
progression fromMCI to AD [26]. Here, we found that levels
of NRGN were significantly reduced in plasma NDEs
derived from stable MCI, ADC, and AD patients compared
to CNC subjects. It is possible that NRGN is released pref-
erentially into CSF and not via exosomes as a result of syn-
aptic damage occurring in AD. The expression of REST in
neurons increases with aging and is markedly decreased in
the brain in AD [18] and Huntington’s Disease [18].
Reduced REST expression has been reported in plasma
NDEs from AD patients [18]. To date, no studies have
been conducted analyzing REST in CSF. We found reduced
protein levels of REST in plasma NDEs derived from ADC
and AD patients, and a smaller reduction, with overlap with
CNC subjects, in stable MCI patients. The trafficking of
REST in neurons and how it may be released through exo-
somes remains to be defined.
The use of blood-based biomarkers for AD diagnostics
could improve effectiveness and reliability of patient
characterization. Well-established protocols have to be
designed, validated, and implemented to demonstrate
their clinical utility, accuracy, and effectiveness in distin-
guishing different patient populations. One study foundthe combination of 18 different proteins in plasma pre-
dicted the progression to AD in stable MCI patients with
over 90% accuracy [41]; however, a subsequent study
demonstrated that the diagnostic accuracy for most of
these markers was not reproducible [42]. High P-tau
levels in CSF have shown to be excellent biomarkers to
detect AD. However, most clinical settings use serum or
plasma for diagnostic testing where P-tau levels are nor-
mally very low in AD patients [43]. Given that recent
in vitro evidence suggests that most tau protein that is pre-
sent in blood is encapsulated in NDEs, validating the use-
fulness of plasma NDE proteins as biomarkers in AD with
standardized assays could improve screening and strati-
fying patients for clinical trials.
Finally, we report for the first time that plasmaNDE cargo
has high pathogenic potential. Plasma NDEs from stable
MCI and ADC patients induced tau pathology in the brains
of normal mice (Fig. 4). Interestingly, we observed more
extensive staining of CA1 pyramidal neurons and of their
dendritic processes in the brains of mice injected with
plasma NDEs from ADC patients. This could be due to
plasma NDEs fromADC patients having a higher concentra-
tion of P-T181-tau and P-S396 as measured by ELISA. As
disease severity increases, it is not clear if the accumulation
of toxic proteins in the brain drives the activation of this
alternative secretory pathway or if the presence of P-tau
and Ab1–42 is due to passive release by dead and/or dying
neurons. Our observation of more PHF-1 positive cells in
the brains of mice injected with plasma NDEs of ADC pa-
tients suggests that the tau species themselves may serve
as the agents of spread. The secretion and release of tau ag-
gregates or “seeds” from neurons has been reported with
other aggregation-prone proteins such as Ab1–42 [22], a-
synuclein [44,45], prion protein [46], and SOD1 [47]. We
cannot exclude that other aggregation-prone proteins may
be trafficked in NDEs from the CNS and potentially propa-
gate pathology in the brain.
In conclusion, our findings suggest that plasma NDE
cargo proteins traffic from the CNS to blood and allow accu-
rate assignment of the stage of development of AD by pre-
dicting the conversion of MCI to AD. Creating a more
detailed profile with additional NDE markers may signifi-
cantly enhance their diagnostic utility for AD as well other
neurodegenerative diseases. Recently, a preliminary study
reported elevated levels of P-tau contained within plasma
exosomes extracted from former National Football League
players compared to a control group of noncontact sport ath-
letes [48]. Although the authors do not report a method to
ensure that their plasma exosomes were derived from a neu-
ral source, these data still suggest that tau-positive exosomes
can act as potential biomarkers for another neurodegenera-
tive disease, chronic traumatic encephalopathy. Our study
is limited by the relatively small number of subjects in
each category and the cross-sectional sampling of plasma.
Further studies need to address how well a panel of NDE
markers may help to stage AD and other neurodegenerative
C.N. Winston et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 63-72 71diseases, and how they change over time in longitudinal
studies. Finally, we plan to characterize the neuropathologic
and behavioral consequences of plasma NDEs derived from
stable MCI and ADC patients injected into normal mice at
longer time points after injection.
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1. Systematic review: Biomarkers of Alzheimer’s dis-
ease (AD) can dramatically clinical trial design and
analysis. Although much biomarker work has
focused on tau phosphorylation, another important
intermediate to consider is neuronally derived exo-
somes (NDE). Better understanding of the trafficking
of NDE from CNS to CSF and blood could be impor-
tant to clarify the pathogenic significance of tau con-
taining exosomes in AD and might contribute to
validate the detection of exosomes as biomarkers of
AD; which in turn could improve clinical trial design
and analysis, increasing the likelihood of successful
drug development.
2. Interpretation: We demonstrate that the protein con-
tent profile of NDE can accurately differentiate AD
from control patients and accurately predict conver-
sion of MCI to AD. In animal models, intrahippo-
campal injection of NDE from MCI and MCI-AD
converters induced tau pathology in na€ıve mice.
3. Future directions: We recommend advancement of
the NDE program for validation in early-mid phase
AD trials to determine the biomarker utility of NDE
content in defining dementia groups (e.g., AD and
MCI). More exploratory trial work could focus on
how treatment regimen impacts NDE content. In
terms of basic science work, our current studies aim
to understand (1) the total number of exosomes in
blood and how they traffic from CNS to periphery,
(2) the portion of exosomes that are neuronally
derived, (3) the profile of pathogenic proteins con-
tained in NDE versus other exosome populations and
(4) how this cargo changes with aging and disease.References
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